Vaxcyte, Inc. Form 8-K Summary
Business Context and Reporting Period
Vaxcyte, Inc. (PCVX), a Delaware corporation, filed this Current Report on Form 8-K on February 2, 2026, regarding events occurring on January 29, 2026. The filing details a public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key metrics include:
- Shares Issued: 11,000,000 shares initially, plus 1,650,000 additional shares upon full exercise of the underwriters' option.
- Public Offering Price: $50.00 per share.
- Price to Company: $47.50 per share.
- Net Proceeds: Approximately $600.2 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Closing Date: February 2, 2026.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report.
Material Changes
The primary material change is the significant increase in the company's cash liquidity resulting from the $600.2 million in net proceeds. The company's share count has increased by 12,650,000 shares.
Outlook, Risks, and Management Commentary
The filing confirms the successful closing of the offering and the full exercise of the 30-day option by the underwriters. The underwriting agreement includes customary representations, warranties, covenants, and indemnification obligations. No specific forward-looking guidance, operational risks, or unusual items were disclosed in this specific text beyond the standard terms of the underwriting agreement.
Investor Verification Checklist
- Verify the updated share count and potential dilution impact on existing shareholders.
- Confirm the use of proceeds as disclosed in the related prospectus supplement (not detailed in this 8-K text).
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods or covenants.
- Check subsequent filings for the impact of the new capital on the company's balance sheet and runway.